1.49
price down icon4.67%   -0.01
 
loading
Beyondspring Inc stock is traded at $1.49, with a volume of 37,531. It is down -4.67% in the last 24 hours and down -15.88% over the past month. BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
37,531
Relative Volume:
2.84
Market Cap:
$60.97M
Revenue:
$1.88M
Net Income/Loss:
$-15.57M
P/E Ratio:
-3.725
EPS:
-0.4
Net Cash Flow:
$-50.09M
1W Performance:
-0.69%
1M Performance:
-15.88%
6M Performance:
-39.66%
1Y Performance:
-45.00%
1-Day Range:
Value
$1.40
$1.66
1-Week Range:
Value
$1.37
$1.66
52-Week Range:
Value
$1.37
$3.625

Beyondspring Inc Stock (BYSI) Company Profile

Name
Name
Beyondspring Inc
Name
Phone
646-528-4184
Name
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Name
Employee
40
Name
Next Earnings Date
2024-08-05
Name
Latest SEC Filings
Name
BYSI's Discussions on Twitter

Compare BYSI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BYSI
Beyondspring Inc
1.49 60.97M 1.88M -15.57M -50.09M -0.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.50 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.50 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
558.18 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.09 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
241.06 26.46B 3.81B -644.79M -669.77M -6.24

Beyondspring Inc Stock (BYSI) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-21 Downgrade BofA Securities Buy → Underperform
Dec-02-21 Downgrade Jefferies Buy → Hold
Dec-01-21 Downgrade H.C. Wainwright Buy → Neutral
Dec-01-21 Downgrade William Blair Outperform → Mkt Perform
Sep-09-21 Initiated Robert W. Baird Outperform
Aug-04-21 Upgrade H.C. Wainwright Neutral → Buy
Apr-05-21 Downgrade H.C. Wainwright Buy → Neutral
Jan-11-21 Initiated BofA Securities Buy
Dec-29-20 Initiated Evercore ISI Outperform
Feb-07-20 Initiated Jefferies Buy
Jan-10-20 Initiated Nomura Buy
Dec-03-19 Initiated William Blair Outperform
Jul-10-19 Reiterated H.C. Wainwright Buy
Apr-30-19 Downgrade Maxim Group Buy → Hold
Oct-25-18 Reiterated Maxim Group Buy
View All

Beyondspring Inc Stock (BYSI) Latest News

pulisher
Mar 30, 2025

BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat

Mar 30, 2025
pulisher
Mar 29, 2025

BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com

Mar 28, 2025
pulisher
Mar 27, 2025

BeyondSpring Inc. (BYSI) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates - Stock Titan

Mar 27, 2025
pulisher
Mar 25, 2025

Global Febrile Neutropenia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And - EIN News

Mar 25, 2025
pulisher
Mar 25, 2025

In-Depth Analysis Of The Global Febrile Neutropenia Market Advancements Highlighted by Key Drivers, Trends,... - WhaTech

Mar 25, 2025
pulisher
Mar 25, 2025

BeyondSpring's PlinabulinA Pipeline In Itself? - RTTNews

Mar 25, 2025
pulisher
Mar 19, 2025

Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve

Mar 19, 2025
pulisher
Mar 09, 2025

BeyondSpring, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics stock tumbles amid IPF trial cancellation - Clinical Trials Arena

Mar 04, 2025
pulisher
Feb 25, 2025

BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

BeyondSpring finalizes significant asset sale - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat

Feb 24, 2025
pulisher
Feb 17, 2025

Cancer Vaccines Market on Track for Major Expansion in - One News Page

Feb 17, 2025
pulisher
Feb 12, 2025

Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online

Feb 12, 2025
pulisher
Feb 05, 2025

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights

Feb 05, 2025
pulisher
Jan 31, 2025

SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World

Jan 31, 2025
pulisher
Jan 29, 2025

BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN

Jan 29, 2025
pulisher
Jan 28, 2025

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times

Jan 28, 2025
pulisher
Jan 28, 2025

BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK

Jan 28, 2025
pulisher
Jan 28, 2025

BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan

Jan 28, 2025
pulisher
Jan 26, 2025

BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat

Jan 26, 2025
pulisher
Jan 15, 2025

Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve

Jan 15, 2025
pulisher
Jan 05, 2025

BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World

Jan 05, 2025
pulisher
Dec 24, 2024

BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com

Dec 24, 2024
pulisher
Dec 18, 2024

Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - The Malaysian Reserve

Dec 18, 2024
pulisher
Dec 17, 2024

CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve

Dec 17, 2024
pulisher
Dec 15, 2024

Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko

Dec 15, 2024
pulisher
Nov 27, 2024

BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat

Nov 27, 2024
pulisher
Nov 27, 2024

BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World

Nov 27, 2024
pulisher
Nov 21, 2024

Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail

Nov 21, 2024
pulisher
Nov 21, 2024

Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR

Nov 21, 2024

Beyondspring Inc Stock (BYSI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$66.10
price down icon 2.65%
$73.33
price down icon 0.15%
$31.60
price up icon 0.06%
$18.91
price down icon 11.53%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 7.93%
Cap:     |  Volume (24h):